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Background: The Contour® Next Link 2.4 blood glucose monitoring system (BGMS), which communicates
wirelessly exclusively with a Medtronic insulin pump, was assessed in 2 separate studies.
Methods: In the laboratory study (N=100), subject capillary ﬁngertip sampleswere tested in duplicate using 3 test
strip lots; accuracy was assessed based on ISO 15197:2013 section 6.3 accuracy criteria (95% within ±15 mg/dl or
±15% of reference for glucose b100 and ≥100mg/dl, respectively). In the clinical trial (N=219), untrained subjects
with diabetes tested capillaryﬁngertip and palm blood samples and completed an ease-of-use questionnaire. BGMS
and YSI glucose analyzer results were compared based on ISO 15197:2013 section 8 accuracy criteria.
Results: In the laboratory study, 100% of resultsmet ISO 15197:2013 section 6.3 accuracy criteria. In the clinical trial,
98.6% of capillary ﬁngertip and 97.2% of palm results from subjects met ISO 15197:2013 section 8 accuracy criteria.
By Parkes-Consensus Error Grid analysis, 100% of subject capillary ﬁngertip results were within Zone A. Based on
questionnaire results, the majority of subjects found the BGMS easy to use.
Conclusions: The BGMS exceeds ISO 15197:2013 section 6.3 and section 8 accuracy criteria in the laboratory and in
the hands of untrained users with diabetes.
© 2015 TheAuthors. Published by Elsevier B.V. All rights reserved. This is an open access article under the CCBY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Self-monitoring of blood glucose (SMBG) is associated with
improved outcomes in people with diabetes [1–5]; for those who use
insulin therapy, in particular, SMBGmay lead to better glycemic control
[5,6]. Results obtained from SMBG can be considered when making
diabetesmanagement decisions, such as lifestylemodiﬁcation and insu-
lin dosing. For people with type 1 or type 2 diabetes who are on insulin
therapy, the use of insulin pumps is increasing and generating a grow-
ing need for complementary SMBG systems [7–9]. Wirelessly linking
blood glucose monitoring systems (BGMSs) and insulin pumps sim-
pliﬁes glycemic management and can provide more accurate insulin
dosing by eliminating manual entry errors [10]. A BGMS that is easy to
use may help to reduce patient-related inaccuracies [11]. In fact, both
patient-related factors (e.g., proper user technique) and analytical fac-
tors (e.g., test strip chemistry) contribute to the accuracy of SMBG re-
sults [12].tem; CGM, continuous glucose
lucose dehydrogenase; IRB,
ion for Standardization; SMBG,
1 760 466 1525.
.
. All rights reserved. This is an openThe Contour® Next Link 2.4 (Bayer HealthCare LLC, Diabetes Care,
Whippany, NJ, USA) is a BGMS that was designed to communicatewire-
lessly exclusivelywith certainMedtronic insulin pumps and continuous
glucose monitors (CGMs). The BGMS utilizes Contour® Next test strips
that contain the ﬂavin adenine dinucleotide–glucose dehydrogenase
(FAD-GDH) enzyme in combination with a proprietary electron media-
tor. The accuracy of a BGMS can be assessed based on guidelines set
forth by the International Organization for Standardization (ISO); up-
dated guidelines were published in 2013, replacing ISO 15197:2003
guidelines. The accuracy of Contour® Next Link 2.4 was assessed in 2
separate studies. In the ﬁrst study, the analytical accuracy of the BGMS
was examined in the laboratory based on ISO 15197:2013 section 6.3
accuracy criteria. In the second study, a clinical trial designed prior to
the establishment of revised ISO guidelines, BGMS accuracy was evalu-
ated based on both ISO 15197:2013 section 8 accuracy criteria and ISO
15197:2003 accuracy guidelines. The primary objective of the clinical
trial was to assess the accuracy of the BGMS with ﬁngertip blood
when used by people with diabetes who had no prior experience with
the system, based on ISO 15197:2003 accuracy guidelines. Additional
objectives included: assessment of subject-obtained ﬁngertip blood
based on ISO 15197:2013 section 8 accuracy criteria, assessment of
trial staff–obtained ﬁngertip and subject palm results based on ISO
15197:2013 section 8 accuracy criteria and ISO 15197:2003 accuracy
guidelines, and to obtain subject feedback on the BGMS and the useraccess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
140 T. Bailey et al. / Clinica Chimica Acta 448 (2015) 139–145guide instructions. The ease of use of the BGMS was assessed in the
clinical trial because the accuracy of SMBG results may be affected by
patient technique.
2. Methods
2.1. Study 1: analytical accuracy (ISO 15197:2013, section 6.3 accuracy
criteria)
Fingertip capillary blood samples from 100 subjects were evaluated
using 3 test strip lots. Each sample was tested in duplicate so that
6 blood glucose meters were utilized per sample (2 meters per test
strip lot; N = 600). Most samples were tested fresh from the ﬁnger
without modiﬁcation; however, to obtain enough samples at the low
end of the distribution, some samples (5) were allowed to glycolyze
for up to 7 h to a lower glucose concentration. Samples were tested in
parallel using a YSI 2300 STAT Plus™ glucose analyzer (YSI Life Sciences,
Inc., Yellow Springs, OH, USA) as a laboratory reference. Per the
manufacturer's performance speciﬁcations, the glucose analyzer preci-
sion is±2%of the reading or 2.5mg/dl (0.2mmol/L),whichever is larger
[13]. All testing was performed at 23 ± 5 °C (73.4 ± 9 °F).
Accuracy was assessed based on ISO 15197:2013 section 6.3
accuracy criteria [14] (i.e., ≥95% of results shall fall within ±15 mg/dl
of the mean YSI reference result for samples with glucose concentra-
tions b100 mg/dl and ±15% for samples with glucose concentrations
≥100 mg/dl). BGMS results were compared with YSI laboratory
reference results using a regression analysis. ISO 15197:2013 section
6.3 criteria also require that ≥99% of individualmeasured glucose values
shall fall within Zones A and B of the Parkes-Consensus Error Grid [15]
for type 1 diabetes; thus, a Parkes-Consensus Error Grid analysis was
performed.
2.2. Study 2: user performance evaluation (ISO 15197:2013 section 8
accuracy criteria)
The clinical trial was conducted at 2 clinical sites and enrolled people
with type 1 or type 2 diabetes aged ≥18 years. Institutional ReviewBoard
(IRB) approval was obtained for the trial protocol, informed consent
forms, and all study documents that required such approval. Each
subject completed the informed consent process before participating in
the trial.
Subjects were excluded from the study if they had previously
participated in a trial using the BGMS, were pregnant, had hemophilia
or another bleeding disorder, or if they had any condition, which in
the opinion of the investigator, would put the subject or study conduct
at risk. During the single study visit, prior to blood glucose testing,
subjects were provided with the BGMS and the instructional materials
(User Guide and Quick Reference Guide) andwere given time to review
thematerials to learn how to use the system; no additional trainingwas
provided. Subjects were randomly assigned to 1 of 3 test strip lots (with
1 lot assigned to 50% of subjects and each of the other 2 lots assigned to
25% of subjects).Table 1
Summary of BGMS results from the laboratory study (ISO 15197:2013 section 6.3).
Glucose
concentration
Number of results within speciﬁed error limits
b100 mg/dl
(n = 186)
±5 mg/dl ±10 mg/dl
160 (86.0%) 183 (98.4%)
≥100 mg/dl
(n = 414)
±5% ±10%
307 (74.2%) 411 (99.3%)
Total
(N = 600)
±5 mg/dl or ±5% ±10 mg/dl or ±1
467 (77.8%) 594 (99.0%)
BGMS, blood glucose monitoring system; ISO, International Organization for Standardization.
a ISO 15197:2013 section 6.3 accuracy criteria.Subjects performed a ﬁngertip puncture to obtain capillary blood for
blood glucose testing, and a palm lancing to obtain blood for an alterna-
tive site testing using the BGMS. Trial staff then obtained a ﬁngertip
capillary blood sample to test the subject's plasma glucose using the
BGMS. The results were compared to laboratory reference results tested
on a YSI laboratory glucose analyzer. Accuracy was assessed based
on ISO 15197:2013 section 8 accuracy criteria and ISO 15197:2003
accuracy guidelines. Per-protocol analyses included regression analysis,
construction of modiﬁed Bland-Altman plots, and Parkes-Consensus
Error Grid analysis [15]. Per protocol, subject capillary ﬁngertip data
points with studentized residuals exceeding ±2.576 (99% range) were
considered outliers for the purpose of regression calculations and
were excluded. Per ISO 15197:2013 section 8 accuracy criteria, the out-
liers are shown on the scatter plot and are represented by a different
symbol.
After blood glucose testing, subjects completed a questionnaire on the
BGMS and instructions for use. Possible responses to the subject question-
naire were: 1 (strongly disagree), 2 (disagree), 3 (neutral), 4 (agree), and
5 (strongly agree). In addition, subjects completed a secondquestionnaire
on diabetes management behaviors; possible responses were 0 (no
answer) and 1 (strongly disagree) to 5 (strongly agree).
3. Results
3.1. Study 1: analytical accuracy (ISO 15197:2013 section 6.3 accuracy
criteria)
A total of 600 BGMS results were obtained by testing 100 capillary
blood samples. The plasma glucose concentration range of the blood
samples was 37 mg/dl to 478 mg/dl, and the hematocrit range was
34.0% to 54.5%.
Analysis of BGMS results based on ISO 15197:2013 section 6.3 accu-
racy criteria showed that 100% (600/600) of results were within
±15mg/dl or±15% of the YSI reference result for sampleswith glucose
concentrations b100mg/dl and ≥100mg/dl, respectively (Table 1). Fur-
thermore, 98.4% (183/186) of results for samples with glucose concen-
trations b100 mg/dl were within ±10 mg/dl of the YSI reference
result, and 99.3% (411/414) of results for samples with glucose concen-
trations ≥100 mg/dl were within ±10% of the YSI reference result.
The regression analysis demonstrated strong agreement between
BGMS results and YSI laboratory reference results (Fig. 1A). Also, all re-
sults (600/600) were within Zone A of the Parkes-Consensus Error Grid
(data not shown).
3.2. Study 2: user performance evaluation (ISO 15197:2013 section 8
accuracy criteria)
3.2.1. Subjects
A total of 221 subjects was screened for the study; of those, 219
enrolled and 218 completed the study (of the screened subjects, there
were 2 screen failures and 1 withdrawn subject). Screened subjects
were aged 18 to 95 years (mean, 52 years) and were divided evenly
by gender (51% male). The majority of subjects (88%) were White,±15 mg/dla ±20 mg/dl
186 (100%) 186 (100%)
±15%a ±20%
414 (100%) 414 (100%)
0% ±15 mg/dl or ±15%a ±20 mg/dl or ±20%
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Fig. 1. Regression analysis of BGMS results versus laboratory reference results from (A) the laboratory study (ISO 15197:2013 section 6.3) and from the clinical trial (ISO 15197:2013 sec-
tion 8) for (B) subject capillary ﬁngertip, (C) trial staff capillary ﬁngertip, and (D) subject palm blood samples.⁎,†,‡ BGMS, blood glucosemonitoring system; YSI, YSI 2300 STAT Plus™ glu-
cose analyzer; ISO, International Organization for Standardization. ⁎Gray lines denote regression lines. †Dashed lines represent ±15 mg/dl or ±15% of YSI plasma value. ‡Per ISO
15197:2013 section 6.3 and section 8 accuracy criteria, statistical outliers were excluded from the regression analyses and are represented by a different symbol. There were no outliers
in the laboratory study. Regression calculations for trial staff–obtained capillary ﬁngertip and subject palm results included all data points because ISO 15197:2013 section 8 does not in-
clude guidelines for these blood samples.
141T. Bailey et al. / Clinica Chimica Acta 448 (2015) 139–145with Black/African American and Asian subjects each constituting 4% to
5% of the study population. In addition,most subjects had some college-
level education (44%), were college graduates (33%), or had a high
school education (19%). Of enrolled subjects, 116 had type 1 diabetes,
102 had type 2 diabetes, and 1 subject had diabetes of unknown type.
The greatest percentage of subjects (41%) tested their blood glucose
N4 times/day; equal proportions (13%) reported testing 4, 3, 2, andTable 2
Summary of BGMS results from the clinical trial (ISO 15197:2013 section 8).
Sample type Glucose concentration Data comparison
Fingertip
b100 mg/dl Subject vs YSI (n = 34)
Trial staff vs YSI (n = 34)
≥100 mg/dl Subject vs YSI (n = 184)
Trial staff vs YSI (n = 184)
Palm
b100 mg/dl Subject vs YSI (n = 29)
≥100 mg/dl Subject vs YSI (n = 182)
BGMS, blood glucose monitoring system; ISO, International Organization for Standardization; Y
a ISO 15197:2013 section 8 accuracy criteria.1 times/day; and few subjects reported testing their blood glucose less
than once daily (6%) or not at all (1%).
Fingertip results were analyzed from 218 subjects for both self-
testing and trial staff testing; 211 subjects had results from palm
blood testing. The glucose concentration range of the subjects' blood
samples, as measured by YSI, was 60 mg/dl to 352 mg/dl for ﬁngertip
blood. Hematocrit measurements were performed in duplicate forNumber of results within speciﬁed error limits
±5 mg/dl ±10 mg/dl ±15 mg/dla ±20 mg/dl
23 (67.7%) 34 (100%) 34 (100%) 34 (100%)
26 (76.5%) 34 (100%) 34 (100%) 34 (100%)
±5% ±10% ±15%a ±20%
128 (69.6%) 172 (93.5%) 181 (98.4%) 184 (100%)
141 (76.6%) 181 (98.4%) 182 (98.9%) 184 (100%)
±5 mg/dl ±10 mg/dl ±15 mg/dla ±20 mg/dl
20 (69.0%) 27 (93.1%) 27 (93.1%) 29 (100%)
±5% ±10% ±15%a ±20%
94 (51.7%) 160 (87.9%) 176 (96.7%) 180 (98.9%)
SI, YSI 2300 STAT Plus™ glucose analyzer.
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Fig. 2. Difference of BGMS results from YSI results for (A) subject capillary ﬁngertip,⁎
(B) trial staff capillary ﬁngertip, and (C) subject palm blood samples from the clinical
trial (ISO 15197:2013 section 8).† BGMS, blood glucose monitoring system; YSI, YSI 2300
STAT Plus™ glucose analyzer; ISO, International Organization for Standardization. ⁎Per
ISO 15197:2013 section 8, statistical outliers are represented by a different symbol.
†Dashed lines represent ±15 mg/dl or ±15% of YSI plasma value.
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Fig. 3. Parkes-Consensus Error Grid analysis of BGMS results using (A) subject capillary
ﬁngertip,⁎ (B) trial staff capillary ﬁngertip, and (C) subject palm blood samples from the
clinical trial. BGMS, blood glucose monitoring system; YSI, YSI 2300 STAT Plus™ glucose
analyzer; ISO, International Organization for Standardization. ⁎Per ISO 15197:2013 section
8, statistical outliers are represented by a different symbol.
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143T. Bailey et al. / Clinica Chimica Acta 448 (2015) 139–145each subject; average hematocrit values ranged from 29% to 55%, with a
mean of 45%.
3.2.2. Accuracy
Evaluation of capillaryﬁngertip results showed that 98.6% (215/218)
of subject- and 99.1% (216/218) of trial staff–obtained results met ISO
15197:2013 section 8 accuracy criteria, and evaluation of subject palm
results showed that 97.2% (205/211) of resultsmet ISO 15197:2013 sec-
tion 8 accuracy criteria. The proportion of BGMS results falling within
speciﬁc error limits of the YSI laboratory reference result for each
sample type is shown in Table 2. Themajority of results for each sample
type also fell within ISO 15197:2003 accuracy guidelines, including
100% (218/218) of subject capillary ﬁngertip results (Supplementary
Table 1).
Regression analysis demonstrated strong agreement between
BGMS results and YSI laboratory reference results for subject- and trial
staff–obtained ﬁngertip results and subject palm results (Fig. 1B, C,
and D, respectively). Modiﬁed Bland-Altman plots of the difference of
BGMS results from YSI reference results for each sample type are
shown in Fig. 2. By Parkes-Consensus Error Grid analysis, 100% (218/
218) of subject-obtained capillary ﬁngertip results were within Zone A
(Fig. 3A). Furthermore, 99.5% (217/218) of trial staff capillary ﬁngertip
results and 99.1% (209/211) of subject palm results were within Zone
A, with the remainder (0.5% [1/218] and 0.9% [2/211], respectively)
within Zone B (Fig. 3B and C).
3.2.3. Subject questionnaires
Based on ease-of-use questionnaire results,most subjects responded
“ strongly agree,” “agree,” or “neutral” that “I ﬁnd themeter easy to use”
(99.5%), “The instructions (User Guide and Quick Reference Guide)
were easy to understand” (97.7%), “The meter display is easy to see
and read (the test result)” (99.1%), “It was easy to understand my test
results” (100%), and “The instructions clearly explain what to do if an
error message is displayed by the meter” (99.5%; Fig. 4A). Based on
diabetes management questionnaire results, the majority of subjects
strongly agreed or agreed that accuracy is important to help with their
ability to manage their diabetes (95.9%), to help with their ability toA
B
Fig. 4. Results of the (A) ease-of-use and (B) diabetes management⁎ questionnaires from the cl
⁎Responses of “choose not to answer” were not included in the analysis. †n = 189. ‡n = 215. §more precisely dose their insulin (96.8%), to help with preventing low
blood sugar (92.1%), and to help with using their results to gain better
control of their diabetes (99.1%; Fig. 4B). In addition, 55.9% of subjects
strongly agreed or agreed that they would continue to use only the
meter and test strips their insurance company pays for, even if a more
accurate meter was available, and 60.2% of subjects strongly agreed or
agreed that they preferred the meter used in the study to the one that
they are currently using.
3.2.4. Safety
There were 8 adverse events (hypoglycemia), all classiﬁed as mild,
anticipated, and non–device-related. All adverse events resolved prior
to the subjects leaving the testing site.
4. Discussion
SMBG is an important aspect of diabetes management, particularly
for people who are on insulin pump therapy and also those who are
on multiple-dose insulin therapy [16,17]; calculating bolus insulin
doses and calibrating continuous glucose monitoring systems both
rely on SMBG results. Inaccurate SMBG results may lead to insulin
dosing errors that worsen hypoglycemia or hyperglycemia [18,19].
Wireless communication between BGMSs and insulin pumps allows
for more convenient transfer of glucose data into the bolus calculator
that patients use to guide insulin dosing. This can eliminate manual
entry errors, contributing to more accurate insulin dosing [20,21].
Wireless communication also enables results to be downloaded for
use in diabetesmanagement software,whichmay improve documenta-
tion of blood glucose values. In addition, optimization of the user
interface of a BGMS may enhance the ease of use of a BGMS, which is
also an important consideration for peoplewith diabetes in order to ob-
tain accurate SMBG results [12,22,23].
The 2 studies reported here demonstrate the accuracy and ease of
use of the Contour® Next Link 2.4 BGMS, which can communicate
wirelessly with an insulin pump. In the laboratory study, 100% of
resultswith the BGMSmet ISO 15197:2013 section 6.3 accuracy criteria.
In the clinical trial, N97% of BGMS results using capillary ﬁngertip orinical trial (ISO 15197:2013 section 8; N= 218). BGMS, blood glucose monitoring system.
n = 217. ||n = 213. bn = 211.
144 T. Bailey et al. / Clinica Chimica Acta 448 (2015) 139–145palm blood samples met ISO 15197:2013 section 8 accuracy criteria, as
well as the ISO 15197:2003 accuracy guidelines. The accuracy of the re-
sults using ISO 15197:2013 accuracy criteria was similar whether the
system was being used by study staff or by people with diabetes who
had no prior experience with the BGMS. In addition, 99.0% of results
were within ±10 mg/dl or ±10% of the YSI reference for samples
with glucose concentrations b100 mg/dl and ≥100 mg/dl, respectively.
Also, the majority of subjects in the clinical trial rated the ease of use
of the BGMS favorably via subject questionnaires. Together, these
results suggest that the BGMS is easy to use without prior training.
Moreover, results of the diabetes management questionnaire show
that the accuracy of SMBG results was an important consideration for
the majority of subjects in the clinical study.
The Parkes-Consensus Error Grid analysis is an assessment of the
clinical signiﬁcance of inaccuracies in SMBG results. There are 5 levels
of increasing risk, with Zones A and B denoting little or no clinical risk
to the patient [15]. The inclusion of a consensus error grid analysis
requirement is new to the ISO 15197 guidelines for 2013 [14] and
demonstrates the importance of considering errors in SMBG results in
a clinical context. In the laboratory study, 100% of results were within
Zone A. In the clinical trial, 100% of subject-obtained capillary ﬁngertip
results were within Zone A, while N99% of trial staff–obtained capillary
ﬁngertip and subject palm results were within Zone A and the remain-
der in Zone B. These results suggest that any inaccuracies that are asso-
ciated with the BGMS present limited clinical risk.
Studies that evaluated several other glucose monitoring systems,
such as the OptiScanner® 5000 system (OptiScan Biomedical Corp.),
Bionime® GM700 (Bionime Corp.), Accu-Chek® Performa (Roche
Diagnostics), Bionime® GM550 (Bionime), and EGV1 (EPS Bio
Technology Corp.), have recently been published in this journal
[24–27]. For the OptiScanner® 5000, 100% of results were within
±15% of the central laboratory glucose measurements, although this
is a point-of-care system for use in intensive care units and uses
spectroscopy rather than test strips to measure the glucose
concentration of blood samples [24]. All (100%) measurements with
the OptiScanner® 5000 fell within Zone A of the Clarke Error Grid. A
study that evaluated the Bionime® GM700 and Accu-Chek® Performa
found that 99.85% and 95.98% of capillary blood sample results, for
each system, respectively, were within ISO 15197:2013 accuracy limits
[25]. In the Bland-Altman analysis, the 95% limit of agreement for capil-
lary blood sample results was −8.7% to +11.7% for the Bionime®
GM700 and−10.0% to+18.7% for the Accu-Chek Performa. It is impor-
tant to note that all blood samples in the studywere obtained and tested
by laboratory staff, and no testingwas performed by people with diabe-
tes. A study of the Bionime® GM550 utilized samples tested by both
technicians and people with and without diabetes [26]. When operated
by people with and without diabetes, 96.2% of ﬁngertip results were in
Zone A of the Clarke Error Grid. When operated by technicians, 99.0%
of results for the ﬁrst test strip lot and 97.1% of results for the second
test strip lot were within Zone A. The accuracy study of the EGV1 also
included results obtained by both trained technicians and people with
diabetes [27]. The study reported that 100% of ﬁngertip results fell with-
in ±15 mg/dl of YSI reference values, and 96.4% of ﬁngertip results fell
within ±15% of YSI reference values for samples with glucose
concentrations b75 mg/dl and ≥75 mg/dl, respectively. In the Clarke
Error Grid analysis, 98% of ﬁngertip readings performed by people
with diabetes were in Zone A and 2% of readings were in Zone B; 99%
of ﬁngertip readings performed by a trained technician were in Zone A
and 1% of readings were in Zone B. It is difﬁcult to make direct compar-
isons due to differences in methods among these studies; however, the
accuracy reported here for the Contour® Next Link 2.4 BGMS is similar
to or higher than the other glucose monitoring systems.
In conclusion, accurate SMBG results are important for effective
glycemic management, especially for the increasing number of people
with diabetes who use insulin pumps [5,9]. The Contour® Next Link
2.4 BGMS demonstrated analytical accuracy in the laboratory study,and a high level of accuracy in the hands of people with diabetes who
had no prior experience with the system in the clinical trial. Moreover,
the majority of subjects in the clinical trial felt that the BGMS was
easy to use.
5. Conﬂict of interest statement
TB has received honoraria from Roche, Sanoﬁ-Aventis, Novo
Nordisk, and Amylin; as well as research support from Animas, Bayer,
BD, Boehringer Ingelheim, Corcept, Bristol-Myers Squibb, Dexcom,
GlaxoSmithKline, Halozyme, LifeScan, Lilly, Medtronic, Merck, Novo
Nordisk, Resmed, Roche, Sanoﬁ-Aventis, and Xoma. Rainier Clinical
Research Center (LJK) has received research grant payments from the
following blood glucose meter companies: Bayer, Roche, Abbott, Alere,
and Johnson & Johnson. JFW, CG, SP, and DB are full-time employees
of Bayer HealthCare, LLC, Diabetes Care. BP was a full-time employee
of Bayer HealthCare, LLC, Diabetes Care at the time these studies were
conducted.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cca.2015.06.001.
Acknowledgments
These studies were supported by Bayer HealthCare, LLC, Diabetes
Care. Medical writing assistance was provided by Nancy Bella, PharmD,
of MedErgy, andwas supported by Bayer HealthCare LLC, Diabetes Care.
References
[1] Franciosi M, Lucisano G, Pellegrini F, et al. ROSES: role of self-monitoring of blood
glucose and intensive education in patients with type 2 diabetes not receiving
insulin. A pilot randomized clinical trial. Diabet Med 2011;28:789–96.
[2] Polonsky WH, Fisher L, Schikman CH, et al. A structured self-monitoring of blood
glucose approach in type 2 diabetes encourages more frequent, intensive, and
effective physician interventions: results from the STeP study. Diabetes Technol
Ther 2011;13:797–802.
[3] Fera T, Bluml BM, Ellis WM. Diabetes ten city challenge: ﬁnal economic and clinical
results. J Am Pharm Assoc (2003) 2009;49:383–91.
[4] Martin S, Schneider B, Heinemann L, et al. Self-monitoring of blood glucose in type 2
diabetes and long-term outcome: an epidemiological cohort study. Diabetologia
2006;49:271–8.
[5] Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels
and glycemic control: the Northern California Kaiser Permanente Diabetes Registry.
Am J Med 2001;111:1–9.
[6] American Diabetes Association. Standards of medical care in diabetes—2013.
Diabetes Care 2013;36:S11–66.
[7] Thabit H, Hovorka R. Closed-loop insulin delivery in type 1 diabetes. Endocrinol
Metab Clin North Am 2012;41:105–17.
[8] Didangelos T, Iliadis F. Insulin pump therapy in adults. Diabetes Res Clin Pract 2011;
93(Suppl. 1):S109–13.
[9] Hanaire H. External insulin pump treatment in the day-to-day management of dia-
betes: beneﬁts and future prospectives. Diabetes Metab 2011;37(Suppl. 4):S40–7.
[10] Penfornis A, Personeni E, Borot S. Evolution of devices in diabetes management.
Diabetes Technol Ther 2011;13(Suppl. 1):S93–102.
[11] Raine CH III. Self blood glucose measuring in the non-insulin-requiring diabetic
patient—to test or not to test. US Endocr Dis 2007;2:49–50.
[12] Ginsberg BH. Factors affecting blood glucose monitoring: sources of errors in
measurement. J Diabetes Sci Technol 2009;3:903–13.
[13] YSI Life Sciences. User's manual, YSI 2300 STAT PLUS: glucose & L-lactate analyzer.
https://www ysi com/File%20Library/Documents/Manuals/YSI-2300-Stat-Plus-
manual-j pdf; 2015.
[14] International Organization for Standardization. ISO 15197:2013(E): in vitro diagnos-
tic test systems—requirements for blood-glucose monitoring systems for self-testing
in managing diabetes mellitus. Geneva: International Organization for Standardiza-
tion; 2013.
[15] Parkes JL, Slatin SL, Pardo S, Ginsberg BH. A new consensus error grid to evaluate the
clinical signiﬁcance of inaccuracies in the measurement of blood glucose. Diabetes
Care 2000;23:1143–8.
[16] Raine CH III, Schrock LE, Edelman SV, et al. Signiﬁcant insulin dose errors may occur
if blood glucose results are obtained from miscoded meters. J Diabetes Sci Technol
2007;1:205–10.
[17] Raine CH III, Pardo S, Parkes JL. Predicted blood glucose from insulin administration
based on values from miscoded glucose meters. J Diabetes Sci Technol 2008;2:
557–62.
[18] Hellman R. Glucose meter inaccuracy and the impact on the care of patients.
Diabetes Metab Res Rev 2012;28:207–9.
145T. Bailey et al. / Clinica Chimica Acta 448 (2015) 139–145[19] Tonyushkina K, Nichols JH. Glucose meters: a review of technical challenges to
obtaining accurate results. J Diabetes Sci Technol 2009;3:971–80.
[20] Potti LG, Haines ST. Continuous subcutaneous insulin infusion therapy: a primer on
insulin pumps. J Am Pharm Assoc (2003) 2009;49:e1-13.
[21] Zisser H, Robinson L, Bevier W, et al. Bolus calculator: a review of four “smart”
insulin pumps. Diabetes Technol Ther 2008;10:441–4.
[22] Klonoff DC, Blonde L, Cembrowski G, et al. Consensus report: the current role of self-
monitoring of blood glucose in non-insulin-treated type 2 diabetes. J Diabetes Sci
Technol 2011;5:1529–48.
[23] Hirsch IB, Bode BW, Childs BP, et al. Self-monitoring of blood glucose (SMBG) in
insulin- and non-insulin-using adults with diabetes: consensus recommendations
for improving SMBG accuracy, utilization, and research. Diabetes Technol Ther
2008;10:419–39.[24] Barassi A, Umbrello M, Ghilardi F, et al. Evaluation of the performance of a new
OptiScanner 5000 system for an intermittent glucose monitoring. Clin Chim Acta
2015;438:252–4.
[25] Huang TY, Chang HW, Tsao MF, et al. Evaluation of accuracy of FAD-GDH- and
mutant Q-GDH-based blood glucose monitors in multi-patient populations. Clin
Chim Acta 2014;433:28–33.
[26] Hsu CT, Wu MH, Kuo CY, Zen JM. Testing quality of a self-monitoring blood glucose
sensor with an auto-coding mechanism when used by patients versus technicians.
Clin Chim Acta 2014;437:62–5.
[27] Chen CC, Lin JJ, Hung ST, Chun PT, Lai YK. The clinical performance of the EGV1 self-
monitoring blood glucose system. Clin Chim Acta 2012;413:1039–44.
